Faulty reasoning signals

• Attempt to Sell a Product or Service - 16.6%
• Red Herring - 12%
• Framing Effect - 11.2%

Article text

Whistleblower takes on health insurance and FDA commissioner candidates

By Allison DeAngelis , Elaine Chen , and Adam Feuerstein

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “ The Readout Loud .” You can reach Allison on Signal at AllisonDeAngelis.01.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast.

STAT reporter Bob Herman joins us to discuss his new series, “Out of Pocket, Out of Reach,” which dives into how soaring costs for health insurance are hurting Americans and small business owners. We also speak with Chris Deacon, who filed a whistleblower lawsuit after spotting how an insurer may have violated contracts to provide health benefits for New Jersey’s state workers.

We also discuss the latest news in life sciences, including Anthropic’s push into drug development and Vertex’s largest-ever acquisition.

To read the “Out of Pocket, Out of Reach” series, go here ; for more information on AstraZeneca and Ionis Pharma’s trial failure, go here ; for more information on the FDA commissioner candidates, go here ; to read about Vertex’s acquisition of Crinetics, go here ; and to read about Claude Science, go here .

Be sure to sign up for “The Readout LOUD” on Apple Podcasts , Spotify , or wherever you get your podcasts.

AstraZeneca , biotechnology , FDA , health care costs , Health insurance , Vertex

Submit a correction request Reprints

Biotech Startups and Venture Capital Reporter

National Biotech Reporter

Senior Writer, Biotech

The mysterious case of Eli Lilly’s obesity drug

New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises

STAT Plus: An obesity drug deep-dive, and peptides move mainstream

What RevMed’s pancreatic cancer drug meant for one patient

STAT Plus: Biotech veteran Jeremy Levin on why the industry’s future is secure, but American leadership is at risk